Drug Profile
Research programme: transdermal therapeutics - Seelos Therapeutics
Alternative Names: Calcipotriene/betamethasone - Seelos Therapeutics; Calcipotriol/betamethasone dipropionate - NexMed; PsoriaVaLatest Information Update: 29 Jan 2019
Price :
$50
*
At a glance
- Originator NexMed
- Developer Apricus Biosciences
- Class
- Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 25 Jan 2019 Seelos Therapeutics merged with Apricus Biosciences to form Seelos Therapeutics
- 21 Sep 2016 Discontinued - Preclinical for Psoriasis in USA (Topical)
- 01 Apr 2011 Preclinical development is ongoing in USA